Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.

Milner EE, Berman J, Caridha D, Dickson SP, Hickman M, Lee PJ, Marcsisin SR, Read LT, Roncal N, Vesely BA, Xie LH, Zhang J, Zhang P, Li Q.

Malar J. 2016 Dec 7;15(1):588.

2.

5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents.

Huang W, Hulverson MA, Zhang Z, Choi R, Hart KJ, Kennedy M, Vidadala RS, Maly DJ, Van Voorhis WC, Lindner SE, Fan E, Ojo KK.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5487-5491. doi: 10.1016/j.bmcl.2016.10.014.

PMID:
27780638
3.

Chemoprophylaxis of Tropical Infectious Diseases.

McBride WJ.

Pharmaceuticals (Basel). 2010 May 18;3(5):1561-1575. Review.

4.

Diagnosis and Treatment of Plasmodium vivax Malaria.

Baird JK, Valecha N, Duparc S, White NJ, Price RN.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171.

5.

Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.

Fasinu PS, Tekwani BL, Avula B, Chaurasiya ND, Nanayakkara NP, Wang YH, Khan IA, Walker LA.

Malar J. 2016 Sep 13;15:466. doi: 10.1186/s12936-016-1509-x.

6.

Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.

Negreiros S, Farias S, Viana GM, Okoth SA, Chenet SM, de Souza TM, Marchesini P, Udhayakumar V, Povoa MM, Santelli AC, de Oliveira AM.

Am J Trop Med Hyg. 2016 Nov 2;95(5):1061-1068.

PMID:
27549633
7.

Management of relapsing Plasmodium vivax malaria.

Chu CS, White NJ.

Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304.

8.

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Ebstie YA, Abay SM, Tadesse WT, Ejigu DA.

Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. Review.

9.

Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.

Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, Vilakati S, Pan S, Darteh S, Maphalala G, Brown J, Hwang J, Pace C, Stergachis A, Vittinghoff E, Kunene S, Gosling R.

Malar J. 2016 Jul 22;15(1):384. doi: 10.1186/s12936-016-1410-7.

10.

Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Nevin RL, Croft AM.

Malar J. 2016 Jun 22;15:332. doi: 10.1186/s12936-016-1391-6. Review.

11.

Current therapies and future possibilities for drug development against liver-stage malaria.

Raphemot R, Posfai D, Derbyshire ER.

J Clin Invest. 2016 Jun 1;126(6):2013-20. doi: 10.1172/JCI82981. Review.

PMID:
27249674
12.

Challenges for malaria elimination in Brazil.

Ferreira MU, Castro MC.

Malar J. 2016 May 20;15(1):284. doi: 10.1186/s12936-016-1335-1. Review.

13.

Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia.

Zuluaga-Idárraga L, Blair S, Akinyi Okoth S, Udhayakumar V, Marcet PL, Escalante AA, Alexander N, Rojas C.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4610-9. doi: 10.1128/AAC.00186-16.

14.

Antimalarial and antimicrobial activities of 8-Aminoquinoline-Uracils metal complexes.

Phopin K, Sinthupoom N, Treeratanapiboon L, Kunwittaya S, Prachayasittikul S, Ruchirawat S, Prachayasittikul V.

EXCLI J. 2016 Feb 18;15:144-52. doi: 10.17179/excli2016-101.

15.

Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes.

Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandara Herath HM, McChesney JD, Reichard GA, Marcsisin SR, Elsohly MA, Khan SI, Khan IA, Walker LA.

Malar J. 2016 Apr 19;15:224. doi: 10.1186/s12936-016-1270-1.

16.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF.

PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423.

17.
18.

Epidemiological and entomological studies of a malaria outbreak among French armed forces deployed at illegal gold mining sites reveal new aspects of the disease's transmission in French Guiana.

Pommier de Santi V, Girod R, Mura M, Dia A, Briolant S, Djossou F, Dusfour I, Mendibil A, Simon F, Deparis X, Pagès F.

Malar J. 2016 Jan 22;15:35. doi: 10.1186/s12936-016-1088-x.

19.
20.

Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.

McFarland AP, Sanchez JF, Mercado A, Ventocilla JA, Cavalcanti S, Gonzalez S, Lescano AG.

Malar J. 2015 Dec 1;14:478. doi: 10.1186/s12936-015-0959-x.

Items per page

Supplemental Content

Support Center